Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754440 | 0.94 | NR1H2 (0.57) | NR1H2NR1H3 | |
| SCHEMBL1754378 | 0.89 | NR1H2 (0.60) | NR1H2NR1H3 | |
| SCHEMBL11997935 | 0.88 | NR1H2 (0.58) | NR1H2NR1H3KDM4EALDH1A1HTT | |
| SCHEMBL1754291 | 0.88 | NR1H2 (0.57) | NR1H2NR1H3KDM4EALDH1A1HTT | |
| SCHEMBL1754491 | 0.87 | NR1H2 (0.68) | NR1H2NR1H3 | |
| SCHEMBL1754382 | 0.86 | NR1H2 (0.61) | NR1H2NR1H3 | |
| SCHEMBL1756045 | 0.86 | NR1H2 (0.51) | NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL1754097 | 0.83 | NR1H2 (0.64) | NR1H2NR1H3KDM4EALDH1A1HTT | |
| SCHEMBL1754248 | 0.83 | NR1H2 (0.57) | NR1H2NR1H3KDM4EALDH1A1HTT | |
| SCHEMBL1754269 | 0.83 | NR1H2 (0.62) | NR1H2NR1H3KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885KDM4E 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.